Startseite>>Zunsemetinib M-atropisomer

Zunsemetinib M-atropisomer (Synonyms: Zunsemetinib M-atropisomer; (M)-ATI-450; ATI-450 M-atropisomer; ATI-450; ATI450; ATI 450; CDD-450 M-atropisomer ; CDD 450; CDD450;)

Katalog-Nr.GB62211

Zunsemetinib M-atropisomer is the inactive isomer of Zunsemetinib.

Products are for research use only. Not for human use. We do not sell to patients.

Zunsemetinib M-atropisomer Chemische Struktur

Cas No.: 1640282-44-5

Größe Preis Lagerbestand Menge
1mg
150,00 $
Auf Lager
5mg
550,00 $
Auf Lager
10mg
950,00 $
Auf Lager
25mg
1.650,00 $
Auf Lager
50mg
2.950,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents
Zunsemetinib M-atropisomer is the inactive isomer of Zunsemetinib. Zunsemetinib, also known as ATI-450 and CDD450, is the P-atropisomer and is a potent MK2 Inhibitor. ATI-450 binds with high affinity to the interface of the p38MAPK-MK2 complex and selectively inhibits p38MAPK-catalysed phosphorylation of MK2 which stabilises the inactive conformation of MK2, and subsequently reduces inflammatory cytokine levels. ATI-450 specifically blocks the downstream MK2-mediated inflammatory drive on the p38 pathway and may therefore avoid the tachyphylaxis associated with p38 inhibitors. Note CAS#1640282-42-3 is the active P-atropisomer. CAS# 1640282-44-5 is the inactive M-astropisomer.

Bewertungen

Review for Zunsemetinib M-atropisomer

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Zunsemetinib M-atropisomer

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.